Category: Uncategorized

Wells Fargo and Operation HOPE Introduce Free Financial Coaching to Small Businesses

New HOPE Inside centers expand financial education program in Wells Fargo branches

NEW YORK–(BUSINESS WIRE)–
Wells Fargo in collaboration with Operation HOPE, a national nonprofit dedicated to financial empowerment for underserved communities, today introduced HOPE Inside for Small Business to provide financial coaching and support to small business customers in key markets at no cost. Starting in Baldwin Hills and Van Nuys neighborhoods of Los Angeles, Calif., and Charlotte, N.C., this expansion builds on the existing HOPE Inside program that helps empower community members to achieve their financial goals through financial education workshops and personalized coaching.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508538267/en/

Wells Fargo first launched HOPE Inside centers in 2022 to serve individuals with their personal finances and help build financial resilience through guidance in areas like budgeting, credit building, and money management. The new Small Business HOPE Inside centers will now offer those same specialized resources for small business owners in addition to business plan development, access to capital education and more. Through one-on-one coaching, entrepreneurs will receive personalized support to help start, grow, and sustain their businesses.

“We know that having access to trusted financial guidance is invaluable,” said April Schneider, head of Small and Business Banking at Wells Fargo. “This kind of continued community investment showcases how important small businesses are to our communities and our commitment to help them thrive.”

HOPE Inside centers are located inside Wells Fargo branches in select markets, and feature Operation HOPE financial coaches who foster financial inclusion and economic empowerment. The branches feature redesigned and updated spaces created to deliver one-on-one consultations, improve digital access, and offer financial health workshops.

“Small businesses are the backbone of our communities, and we want to provide them with the tools and resources they need to succeed,” said Michael Martino, head of Banking Inclusion Initiative at Wells Fargo. “Expanding HOPE Inside to support small businesses is a natural evolution of our work with Operation HOPE and reinforces our shared vision of building stronger, more financially resilient communities.”

“Strategic partnerships are the backbone of community transformation and Wells Fargo has been with us since the beginning. We are deeply grateful for their commitment to increasing economic inclusion by expanding our HOPE Inside for Small Business footprint,” said John Hope Bryant, founder, Chairman and CEO, Operation HOPE. “This collaboration empowers aspiring entrepreneurs and small business owners with financial coaching and education — meeting them where they are and helping them build a future rooted in financial confidence and success.”

The expansion is part of a broader national effort through Wells Fargo’s Banking Inclusion Initiative to bring HOPE Inside to 50 markets across the U.S. by 2026. Currently at 30 HOPE Inside centers, serving over 100 branches, the impact of the program has helped more than eleven thousand clients since launching in 2022. All services offered through HOPE Inside are at no cost and available to community members, whether they are Wells Fargo customers or not.

Wells Fargo’s Banking Inclusion Initiative was started in 2021 to help more people who are unbanked gain access to affordable, mainstream banking products, and financial education.

About Wells Fargo

Wells Fargo & Company (NYSE: WFC) is a leading financial services company that has approximately $1.9 trillion in assets. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth & Investment Management. Wells Fargo ranked No. 34 on Fortune’s 2024 rankings of America’s largest corporations. News, insights, and perspectives from Wells Fargo are also available at Wells Fargo Stories.

Additional information may be found at www.wellsfargo.com.

LinkedIn: https://www.linkedin.com/company/wellsfargo

WF-BL

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508538267/en/

Media

Aryel Bell, 704-787-3420

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Entrepreneur Finance Consulting Banking Business Professional Services Hispanic Small Business Consumer

MEDIA:

Photo

Wells Fargo HOPE Inside for Small Business – three people walking past Wells Fargo branch (Credit: Wells Fargo)

Rahway Public Schools Deploys Evolv Technology to Enhance Student Safety

Rahway Public Schools adopts Evolv Express^® and Evolv eXpedite™ to strengthen entryway safety

WALTHAM, Mass.–(BUSINESS WIRE)–
Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced its partnership with Rahway Public Schools in Rahway, NJ. The district recently installed Evolv Express^® and Evolv eXpedite™ systems at its gymnasium and performing arts entrances, marking a significant step forward in school security. The combination of Express and eXpedite will allow students to be screened without having to take laptops out of their bags.

“Our top priority is the safety and well-being of our staff, students, and families,” said Dr. Shoieb, Superintendent of Rahway Public Schools. “With Evolv, we are able to screen students efficiently without compromising their sense of security or disrupting their day. We’re proud to be the first school district in New Jersey to implement the eXpedite solution in combination with Express to help detect threats without putting an excess burden on our staff.”

“This partnership reflects Rahway’s proactive commitment to student safety,” said Dean Marcantonio, Director of Safety and Security for Rahway Public Schools. “The integration of Evolv’s systems is a game-changer for how we think about securing our schools.”

“We are honored to support Rahway Public Schools in their commitment to student safety,” said John Kedzierski, President and Chief Executive Officer of Evolv Technology. “Since Evolv eXpedite’s launch in September 2024, we have seen momentum among customers who have begun to add the system into their layered safety plan. Rahway is setting the standard for how schools can use innovative technology to provide an efficient and welcoming environment for learning.”

With this deployment, Rahway Public Schools joins over 1,100 school buildings nationwide that are turning to Evolv’s advanced security technology to help enhance safety while maintaining welcoming learning environments. Evolv remains committed to helping educational institutions protect their communities with solutions that are fast, intelligent, and efficient.

About Evolv Technology

Evolv Technologies Holdings, Inc (NASDAQ: EVLV) is designed to transform human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered screening and analytics. Its mission is to transform security to create a safer world to live, work, learn, and play. Evolv has digitally transformed the gateways in many places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than two billion people since 2019. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) 2024 New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category, as well as Sport Business Journal’s (SBJ) 2024 awards for “Best In Fan Experience Technology” and “Best In Sports Technology”. Evolv^®, Evolv Express^®, Evolv Insights^®, Evolv Visual Gun Detection™, Evolv eXpedite™, and Evolv Eva™ are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit evolv.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Evolv Technology intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements made in the quotes from executives and directors and statements regarding the Company’s execution of its strategy, financial and operational performance and growth and creating value for stakeholders. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results and actions to be materially different from any future results or actions expressed or implied by the forward-looking statements, including, but not limited to, the factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on April 28, 2025 as any such factors may be updated from time to time in our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. . The forward-looking statements in this press release are based upon information available to us as of the date hereof, and while we believe such information forms a reasonable basis for such statements, it may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508665290/en/

Investor Relations:

Brian Norris

[email protected]

Media Relations:

Alexandra Smith Ozerkis

[email protected]

KEYWORDS: United States North America Massachusetts New Jersey

INDUSTRY KEYWORDS: Primary/Secondary Education Security Technology Other Education Artificial Intelligence

MEDIA:

Logo

Easterly Government Properties Acquires 74,549 SF U.S. Department of Homeland Security Law Enforcement Support Center, 100% Leased, and Located Near Burlington, Vermont

• Law enforcement operations run from this facility 24 hours a day, seven days a week, 365 days a year across three separate shifts

WASHINGTON–(BUSINESS WIRE)–
Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, announced today that it has acquired a 74,549 square foot facility primarily leased to the U.S. Department of Homeland Security (DHS) located near Burlington, Vermont (“DHS – Burlington”).

DHS – Burlington is a 100% leased build-to-suit facility, designed to the exact specifications of the U.S. Government. This Level IV secure facility includes support from U.S. Customs and Border Protection (CBP), U.S. Immigration and Customs Enforcement (ICE), and ICE’s Law Enforcement Support Center (LESC). This 10-year non-cancelable General Services Administration (GSA) lease does not expire until May 2031.

As the primary occupant in the facility, LESC plays an integral role in the DHS’s efforts to protect and defend the United States and serves as a single, national point of contact 24 hours a day, seven days a week, 365 days a year across three separate shifts. Agents within this facility provide a diverse support system to federal, state, tribal and local law enforcement agencies through LESC’s Enforcement Unit, which delivers immediate telephonic information to identify criminal threats, near real-time investigative referrals, and arrest warrant validation. Similarly, its Operations Unit processes biometric and biographic Immigration Alien Queries (IAQs) originating from law enforcement agencies across the country.

“Our acquisition activity continues to enhance our ability to deliver earnings growth to shareholders,” said Darrell Crate, President & Chief Executive Officer of Easterly Government Properties. “With this asset, we continue to increase our cash flows derived from federal agency tenants like the DHS and facilitate operations which remain mission-critical to the safety and security of the United States.”

With this acquisition, Easterly owns, directly or through the Company’s joint venture, 102 properties totaling 10.2 million square feet.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

This press release contains forward-looking statements within the meaning of federal securities laws and regulations. These forward-looking statements are identified by their use of terms and phrases such as “believe,” “expect,” “intend,” “project,” “anticipate,” “position,” and other similar terms and phrases, including references to assumptions and forecasts of future results. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those anticipated at the time the forward-looking statements are made. These risks include, but are not limited to those risks and uncertainties associated with our business described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed on February 25, 2025. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that the expectations will be attained or that any deviation will not be material. All information in this release is as of the date of this release, and we undertake no obligation to update any forward-looking statement to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508083803/en/

Easterly Government Properties, Inc.

Lindsay S. Winterhalter

Senior Vice President, Investor Relations & Operations

202-596-3947

[email protected]

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Professional Services Public Policy/Government Commercial Building & Real Estate Construction & Property Homeland Security REIT

MEDIA:

Logo

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

• Proceeds intended to support Hims & Hers’ global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care

SAN FRANCISCO–(BUSINESS WIRE)–
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $67.5 million aggregate principal amount of notes.

Hims & Hers intends to use proceeds from the offering for general corporate purposes, including accelerating global expansion through both organic growth and strategic acquisitions. Hims & Hers has no definitive agreements for any material acquisitions at this time. The funds will also support the technology team, led by newly appointed CTO Mo Elshenawy, to expand the Company’s data pipeline, develop AI tools, and advance personalized treatments to enhance the consumer healthcare experience. In addition, a portion of the net proceeds will be used to fund the cost of entering into the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, a portion of the additional proceeds will also be used to fund the cost of entering into the related capped call transactions.

The notes will be senior, unsecured obligations of Hims & Hers, will accrue interest payable semi-annually in arrears and will mature on May 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Hims & Hers will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at the Company’s election.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Company’s option at any time, and from time to time, on or after May 19, 2028 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of the Company’s Class A common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If certain corporate events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Hims & Hers to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

In connection with the pricing of the notes, Hims & Hers expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or one or more other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to the Company’s Class A common stock upon any conversion of the notes and/or offset any potential cash payments Hims & Hers is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap.

If the initial purchasers exercise their option to purchase additional notes, then Hims & Hers expects to enter into additional capped call transactions with the option counterparties. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to the Company’s Class A common stock and/or purchase shares of the Company’s Class A common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company’s Class A common stock or the notes at that time.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company’s Class A common stock and/or purchasing or selling the Company’s Hers’s Class A common stock or other securities of Hims & Hers in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so (x) during any observation period related to a conversion of notes or following any repurchase of notes by Hims & Hers in connection with any redemption or fundamental change or (y) following any other repurchase of notes by the Company if the Company elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or decrease in the market price of the Company’s Class A common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes.

The offer and sale of the notes and any shares of Class A common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Class A common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Hims & Hers

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

Forward-Looking Statements

Except for historical information, certain statements in this press release, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering, the intended use of the proceeds and the anticipated terms of, and the effects of entering into, the capped call transactions described above, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business, including, without limitation, risks and uncertainties related to market conditions, including market interest rates, the trading price and volatility of the Company’s Class A common stock and risks relating to the Company’s business. Hims & Hers may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Hims & Hers does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the “Risk Factors” section in the Company’s most recently filed Quarterly Report on Form 10-Q and its most recently filed Annual Report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508416714/en/

Investor Relations

Bill Newby

[email protected]

Media Relations

Farshad Shadloo

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Vitamins/Supplements Women Men Telemedicine/Virtual Medicine General Health Pharmaceutical Consumer Health Artificial Intelligence

MEDIA:

Logo

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

– Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 –

– Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications –

– Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) –

– Second Phase 3 study, EMBRACE, is expected to begin mid-2025 –

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.

The patent, which is expected to provide exclusivity until 2041, includes claims to pharmaceutical compositions and oral dosage forms within the Company’s proprietary deuterated psilocin analog program, CYB003.

“Securing an additional patent in support of CYB003 provides important validation of our program and reinforces the commercial potential of our pipeline,” said Doug Drysdale, Chief Executive Officer of Cybin. “Robust patent protection is essential for drug development companies, and we are proud of our expanding intellectual property portfolio. As we continue to dose patients in our first Phase 3 study, we are focused on execution, delivering shareholder value, and ultimately, creating more effective treatments for those with mental health disorders.”

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s expectations respecting the patent exclusivity period; commencement of the second Phase 3 study, EMBRACE, in mid-2025; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company’s profile on SEDAR+ www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508891960/en/

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

[email protected] – or – [email protected]

KEYWORDS: United States North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Mental Health Health Neurology Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo